Search PubMed⌕ Search

Biomedical subjects

Y Okabayashi

Publications and source records attributed to Y Okabayashi.

At least 91 records · Page 5Linked to original sources
PubMed1986

Effect of Bt2cGMP on action of cholecystokinin in isolated perfused rat pancreas.

We have examined the effects of Bt2cGMP on cholecystokinin stimulation of pancreatic exocrine secretion in the isolated perfused rat pancreas. Bt2cGMP produced a concentration-dependent inhibition of the stimulatory effects of cholecystokinin octapeptide (CCK-8, 100 pM) on both pancreatic juice flow and enzyme secretion. Adding 1 mM Bt2cGMP rapidly and completely abolished CCK-8-stimulated pancreatic juice and enzyme secretion. Adding 500 microM Bt2cGMP for 10 min at the termination of 1 nM of CCK-8 infusion caused an immediate and persistent inhibition of the residual response. In contrast, treatment with C-terminal CCK antiserum I had no influence on the residual response. To account for the ability of Bt2cGMP to function as a competitive antagonist of the action of CCK and the ability of the nucleotide to inhibit the residual stimulation caused by CCK, we feel that Bt2cGMP hindered the binding of CCK not only by reducing the association rate constant for hormone binding but also accelerating the dissociation rate.

Amylases↗
PubMed1986

Dibutyryl guanosine 3',5'-monophosphate inhibits cholecystokinin potentiation of insulin release in the isolated perfused rat pancreas.

(Bu)2cGMP is known to act as a specific competitive inhibitor for gastrin and cholecystokinin (CCK) peptides. We have examined the effects of (Bu)2cGMP on CCK octapeptide (CCK-8) stimulation of insulin release in the isolated perfused pancreas and compared them with those on protein output. Addition of (Bu)2cGMP after a 20-min perfusion with 100 pM CCK-8 resulted in two distinctly different phases of insulin suppression. There was a sharp initial decline in insulin release for 3 min, followed by transient recovery toward the control level for 5 min, and then a small decline until termination of (Bu)2cGMP infusion. (Bu)2cGMP produced a concentration-dependent inhibition of both phases of insulin decrement. (Bu)2cGMP also produced a concentration-dependent inhibition of protein output. Addition of 1 mM (Bu)2cGMP rapidly and completely abolished CCK-8-stimulated protein output. Since CCK is released by meal intake and exogenous CCK stimulates insulin release and augments glucose-induced insulin release, it is possible that endogenous CCK plays an important role in the enteroinsular axis. The present findings of blockade of CCK-8-induced insulin release by selective antagonist of the action of CCK provide evidence for CCK as a mediator in the enteroinsular axis.

Animals↗
PubMed1985

Exocrine pancreatic function in rats after acute trypsin inhibitor treatment.

A single oral dose of synthetic trypsin inhibitor (TI, 20 mg/100 g) was given to rats by orogastric tube 6, 12, 18, or 24 hr before the removal of the pancreas and the preparation of isolated perfused pancreas. TI treatment induced no significant changes in body weight and total amount of DNA content in the pancreas, but pancreatic wet weight, total pancreatic protein and amylase, and the concentration of total protein and amylase relative to DNA were significantly decreased at 6 or 12 hr posttreatment, with a partial return toward control values at 18-24 hr after TI treatment. In isolated perfused pancreas, basal amylase output was similar in the control and in all 4 groups of TI-pretreated rats, while basal rate of flow of pancreatic juice was significantly increased at 12-24 hr posttreatment. Caerulein (0.1 ng/ml; 64 pM) stimulated pancreatic juice flow was greatly increased in rats pretreated with TI 12-24 hr earlier. In contrast, caerulein-stimulated amylase output was significantly lower in TI-pretreated groups compared with the control. However, when amylase output was related to the total content in the pancreas, the secretory responsiveness for amylase release was significantly higher in rats at 6-18 hr posttreatment compared with the control. The present study indicates that a single oral administration of TI modulates biological response to caerulein in the isolated perfused pancreas. The enhanced responsiveness of amylase release to subsequent stimulation is seen in early periods, while that of pancreatic juice flow is observed in late periods.

Amylases↗
PubMed1985

Comparative inhibitory effects of pirenzepine and atropine on cholinergic stimulation of exocrine and endocrine rat pancreas.

The effects of pirenzepine on carbamylcholine-stimulated exocrine and endocrine pancreatic functions were compared with those of atropine in both the isolated pancreatic acini and the isolated perfused pancreas of rats. In the isolated acini pirenzepine and atropine produced a concentration-dependent inhibition of amylase secretion initiated by carbamylcholine. This inhibition resulted in a rightward shift in the dose-response curve for carbamylcholine-stimulated amylase secretion without altering the maximal increase in amylase secretion. Pirenzepine was, however, approximately 300 times less potent than atropine in inhibiting the stimulated amylase release. A similar difference in potency was observed with respect to carbamylcholine stimulation of pancreatic juice, amylase, and insulin release from the isolated perfused pancreas. The maximal inhibitory concentration of pirenzepine on a maximal effective concentration of pirenzepine on a maximal effective concentration of carbamylcholine for stimulating pancreatic exocrine secretion was 10 microM, whereas that of atropine was 30 nM. The present data define the pirenzepine receptors in the exocrine and endocrine pancreas as low-affinity-type receptors.

Amylases↗
PubMed1985

Relationship between the severity of diabetes mellitus and pancreatic exocrine dysfunction in rats.

The relationship between the severity of diabetes mellitus and pancreatic exocrine function was investigated in rats made diabetic by injecting 3 different doses of streptozotocin (30, 45 or 60 mg/kg body weight). The expected correlation was obtained between the dose of streptozotocin and degree of elevation of blood glucose and decrease in pancreatic insulin content. Pancreatic amylase content of the diabetic rats was less than that of control rats and was in parallel with less values in pancreatic insulin content. On the other hand, trypsinogen content of diabetic rats was greater than that of control. Basal and caerulein-stimulated flow rates of pancreatic juice and protein output were similar in the control and in all 3 groups of diabetic rats. In contrast, there was a graded response of amylase and trypsinogen, depending upon the content of each enzyme in the pancreas. Both basal and caerulein-stimulated amylase outputs from diabetic rat pancreas were significantly reduced in parallel with the severity of diabetic state, but were similar to those from the control rats when related to the total pancreatic content. The present findings indicate that pancreatic exocrine dysfunction in diabetes mellitus is closely related to the severity of the disease, but the secretory dynamics in the perfused pancreas are not altered.

Amylases↗
PubMed1985

Interaction of caerulein, glucose, and amino acids on insulin secretion from the perfused rat pancreas.

The effect of caerulein on insulin response to graded amounts of glucose from the isolated perfused rat pancreas was investigated in the presence or absence of an amino acids mixture. Caerulein at a concentration of 0.1 ng/ml which is a submaximal concentration for an effect on exocrine pancreatic secretion potentiated insulin responses to glucose concentrations less than 200 mg/dl, but produced no further increase when added to a glucose stimulus over a 200 mg/dl. However, in the presence of amino acids the insulin response to 200 mg/dl glucose was significantly potentiated by the stimulation of 0.1 ng/ml caerulein. The effectiveness of caerulein as an insulinotropic agent depended on the glucose concentration only when amino acids were present. These results indicate that caerulein, at a concentration which stimulate pancreatic exocrine secretion, has a synergistic effect on insulin response to glucose and amino acids and therefore raises the possibility that endogenously released CCK may contribute to the entero-insular axis.

Amino Acids↗
PubMed1984

Serum pancreatic secretory trypsin inhibitor in pancreatic disease.

The clinical usefulness of serum pancreatic secretory trypsin inhibitor (PSTI) in pancreatic diseases was evaluated. The mean serum PSTI level of 41 healthy normal persons was 9.4 ng/ml (ranging from 5.2 to 16.7 ng/ml). Serum PSTI levels were abnormally raised in all patients with acute pancreatitis ranging from 35.0 to 4500 ng/ml, but were almost within normal range in patients with chronic pancreatitis, pancreatic cyst, acute abdominal emergencies such as perforated ulcer and intestinal obstruction, and macroamylasemia. There was no correlation between serum PSTI levels and total or pancreatic-type isoamylase activity. Patients with acute pancreatitis in whom the elevation of serum PSTI was transient and occurred after that of serum amylase activity had relatively mild symptoms and recovered along with normalization of serum PSTI levels. On the other hand, patients whose serum PSTI values became increased coincidentally with serum amylase activity and remained elevated, had severe clinical symptoms and unfavorable clinical outcome. Of 2 patients who underwent partial pancreatectomy, the serum PSTI level increased markedly in one who developed postoperative pancreatitis but not in the other without pancreatitis. In contrast to patients with acute pancreatitis, the serum response to the secretin stimulation in patients with chronic pancreatitis, was only small and transient, reaching the maximum at 10 min after administration of secretin. These results suggest that measurement of serum PSTI concentration may be useful in the diagnosis of acute pancreatitis and that the degree of rise and the duration of the elevated levels of serum PSTI are closely related to the severity of acute pancreatitis.

Acute Disease↗
PubMed1984

Amylase inhibitor from wheat: its action and clinical application.

The electrophoretic and column chromatographic characteristics of an amylase inhibitor of wheat origin were investigated. Further, the clinical usefulness of this inhibitor for determining the ratio of pancreatic to salivary isoamylase activity in serum was evaluated. Amylase inhibitor inhibits the action of salivary alpha-amylase by making an amylase-inhibitor complex, which is easily separated into its individual component during electrophoresis with full recovery of amylase activity. Using the specific inhibitory effect of this inhibitor on salivary alpha-amylase activity, the ratio of pancreatic to salivary isoamylase activity (P/S) in serum was determined. There was a good correlation in P/S ratio in serum between the results obtained with the inhibitor method and those with electrophoretic method. The P/S ratio in sera from patients with acute pancreatitis was over 8.0, whereas that in sera from patients with salivary-type hyperamylasemia such as mumps, pulmonary diseases and following surgery was less than 0.1. However, hyperamylasemia due to macroamylase or renal failure could not be identified by the inhibitor method.

Amylases↗
PubMed1984

Amylase secretion by isolated pancreatic acini after acute cholecystokinin treatment in vivo.

A single dose of synthetic cholecystokinin octapeptide (CCK8, 5 micrograms/kg) in a depot carrier was injected subcutaneously into rats 2 and 14 h before the removal of the pancreas and the preparation of isolated pancreatic acini. CCK8 treatment induced no significant change in body weight or total amount of pancreatic DNA, but pancreatic weight, total pancreatic protein and amylase, and the concentration of amylase and total protein relative to DNA were significantly decreased. In acini prepared from CCK8-pretreated rats, responsiveness to maximal and supramaximal concentrations of CCK8 was significantly increased, irrespective of whether the amount of amylase released was expressed relative to DNA or calculated as a percentage of the acinar content. The dose-response curves for CCK8 were similarly shaped in both CCK8-pretreated and control rats but shifted threefold toward higher concentrations of CCK8 2 or 14 h after CCK8 treatment. Specific 125I-CCK binding was significantly increased only for high-affinity binding sites. Although these observations suggest that alterations in pancreatic amylase release could be due to changes at the cholecystokinin receptor, the secretory responsiveness to maximal and supramaximal concentrations of carbachol was also increased without any change in the sensitivity. Moreover, in contrast to the cholecystokinin receptor, there was no change in the number of muscarinic receptors or in their affinity for either agonists or antagonists measured with [3H]quinuclidinyl benzilate.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1983

Effect of acarbose on exocrine and endocrine pancreatic function in the rat.

Exocrine and endocrine pancreatic function were studied simultaneously in the isolated perfused pancreas from rats fed a normal or an acarbose-containing diet (150 mg/100 g food) for 20 days. Body weight gain of acarbose-treated rats was slightly lower than that of control rats, despite a larger food intake. Basal and caerulein-stimulated flow rates of pancreatic juice from acarbose-treated rat pancreases were similar to those from controls, suggesting that the treated rat pancreas has normal sensitivity and responsiveness to caerulein. On the other hand, amylase output in response to caerulein was significantly decreased in acarbose-treated rat pancreases, though basal output was normal. The addition of acarbose to the diet for 20 days had no effect on the speed of the insulin response to glucose and caerulein, but the magnitude of insulin secretion to glucose stimulation was reduced by 40% and the caerulein-induced additional output of insulin by 30% in the treated group as compared with the control group. The present investigation has demonstrated that inhibition of key enzymes for carbohydrate digestion decreases not only the secretory responsiveness of amylase from acinar cells to caerulein stimulation but also the sensitivity of the insulin-secretory mechanism of pancreatic B cells to glucose and non-glucose stimulation.

Acarbose↗
PubMed1983

Exocrine and endocrine pancreatic function in rats treated with alpha-glucosidase inhibitor (acarbose).

Pancreatic exocrine and endocrine secretory dynamics were studied in the isolated perfused pancreata of rats fed a normal diet or a diet supplemented with the alpha-glucosidase inhibitor, acarbose (150 mg/100 g food). After 10 days, the body weight of acarbose-treated rats was slightly lower than that of the control rats despite a larger food intake. Pancreatic amylase levels were significantly decreased, trypsinogen levels were significantly increased, and lipase levels were unaltered in the treated group compared with the controls. Basal and caerulein-stimulated flow rates of pancreatic juice as well as basal amylase output were similar in both groups, whereas caerulein-stimulated amylase output was significantly lower in the acarbose-treated group. Secretory responsiveness of amylase in the treated group was, however, about twice as high as that in the control group when related to pancreatic amylase content. Insulin release in response to either glucose or cerulein was similar in both groups. These findings indicate that treatment with acarbose may alter pancreatic enzyme content without changing the secretory responsiveness of either the exocrine or endocrine pancreas.

Acarbose↗